Timestamps:

1:30 - Working for neon

10:22 - Why you should start investing

15:41 - Start investing with findependent

21:44 - Fee structure

36:26 - 5 principles for personal finance

Click here to enjoy three months of NordPass Business for free by using the code “swisspreneur”.

About Matthias Bryner:

Matthias Bryner is the founder of findependent, an app to make investing transparent, easy and beneficial for everyone, regardless of prior knowledge. He holds an MA in Banking and Finance from HSG and interned at Credit Suisse and at neon before starting findependent in 2018.

findependent allows you to open an account online within approx. 15 minutes, easily select an optimally-tailored investment solution and get started with as little as CHF 500. Thanks to their investment app, findependent users are always informed transparently about their investments, earnings and fees.

But first things first: why should you start investing? Basically, because of inflation and the compounding effect. Inflation rises at least 1% or 2% every year, which means that over the long run your savings will be significantly devalued. Similarly, if you start investing now, even if you invest only a little bit each year, this compounds over time and will make a significant difference in your life later on.

findependent encourages its users to invest in ETFs, which is basically like buying a very small percentage of the world economy, instead of investing in a specific stock. This derisks your investment. And even if the numbers in the market fluctuate daily, their overall historical tendency is upwards, so you can rest assured that your money is being put to good use. findependent currently has 12'000 customers.

Don’t forget to give us a follow on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, so you can always stay up to date with our latest initiatives. That way, there’s no excuse for missing out on live shows, weekly giveaways or founders' dinners.

Timestamps:

8:49 - Pivoting your marketing

12:17 - The key ingredients for sports recovery

17:43 - Distributing through several channels

23:22 - Importing CONDA to Switzerland

33:25 - Developing crowdfunding momentum

This episode was co-produced with CONDA.ch. If you want to invest in CONDA.ch with preferential conditions, contact them at investor@conda.ch.

About Pedro Schmidt & Linus Gabrielsson:

Pedro Schmidt is the founder and CEO of KaEx, the world’s first sports-recovery drink to significantly reduce the stress hormone. He holds a MSc in Management, Technology and Economics from ETH Zürich, and previously worked for companies like Siemens Management Consulting, Bristol-Myers Squibb and Teva Pharmaceuticals before founding KaEx in 2016.

Linus Gabrielsson is the managing director at CONDA.ch, the leading platform providing Swiss startups access to crowd investment capital as well as community building and campaigning opportunities. He holds a MSc in Technology Management from ETH and previously worked for companies like IBM Business Consulting Services, PwC and HSBC Private Bank before founding CONDA.ch in 2021.

KaEx was the result of many years of research for Pedro, whose undergraduate education is in Pharmaceutical Sciences. He originally branded it as a hangover remedy, and that’s how it began to be sold in pharmacies and at Coop supermarkets. At some point, Pedro and his team started getting messages from people who swore on the benefits of drinking KaEx post-workout. Pedro ignored these messages at first, since as a resource-constrained founder he couldn’t afford to split his focus — but then pro-athletes started contacting him as well, asking if drinking KaEx could be considered doping (which it couldn’t). This made Pedro and his team seriously question whether they should pivot their product’s branding and focus. They eventually did do so, and nowadays KaEx is known primarily as a sports drink, though it is of course also useful for hangovers or after a particularly stressful day.

In 2021, CONDA.ch was already one of the most successful crowdfunding platforms in Austria and Germany. Rather than try to compete with them, Linus and his co-founder Christian Klumpe decided to strike a franchising deal with their DACH counterparts in order to bring CONDA to Switzerland. As a crowdfunding platform, they focus on startups, SMEs and real estate, and allow users to invest as little as CHF 100. CONDA.ch always runs a 2 week pre-round with preferential conditions open only to VIP investors: that way, when the deal goes public, it never starts at 0, which helps it gain momentum.

KaEx has crowdfunded on CONDA.ch several times.

Timestamps:

5:15 - Having a co-founder pass away

10:33 - Drug resistance and cancer patients

18:24 - Clinical development

23:17 - Raising a series A as a biotech

26:43 - Striking partnerships

Check out the LinkedIn event for our livestream with Aurelio Perucca on May 22nd.

About Stefanie Flückiger-Mangual:

Stefanie Flückiger-Mangual is the co-founder and CEO at TOLREMO Therapeutics, a biotech startup on a mission to prevent non-genetic cancer drug resistance. She holds a PhD in Molecular and Translational Biomedicine from ETH and worked there as a Postdoctoral Researcher before starting TOLREMO in 2017 together with Wilhelm Krek, who has since tragically passed away.

There is no shortage of cancer therapies in biotech and medtech, and one common problem that they face is drug resistance: even if a certain therapy is at first successful in reducing the tumor’s size, patients sometimes develop a resistance to it, whether it be genetic or non-genetic, and the therapy stops working. To use a tech metaphor, genetic drug resistance is akin to a hardware problem, whereas non-genetic drug resistance is more similar to a software malfunction. Since non-genetic resistance is much more dynamic, it’s harder to measure and combat — this is what Stefanie and her fellow researchers have been studying for the past few years. They discovered a pivotal mechanism that governs critical transcriptional resistance pathways, i.e., that stops cancer drug resistance as it emerges without interfering with cancer-unrelated pathways.

TOLREMO recently completed its Series A financing, bringing their total amount raised to USD 39M. Their ultimate goal is to prove the efficacy of their treatment and join forces with a larger pharma company.

Don’t forget to give us a follow on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, so you can always stay up to date with our latest initiatives. That way, there’s no excuse for missing out on live shows, weekly giveaways or founders' dinners.